$PLRZSep 2, 2026, 11:32 AMAI processed
Polyrizon completes contracts at all 5 U.S. sites for NASARIX first-in-human allergy trial
AI Summary
Polyrizon (PLRZ) said it has executed contracts with all five U.S. clinical sites for its first-in-human NASARIX (PL-14) allergy blocker study and is moving the program into study execution, including patient pre-screening and enrollment preparations. The prospective, multicenter, randomized single-blind trial plans to enroll up to 120 patients randomized 1:1 to NASARIX vs isotonic saline, with the primary endpoint of mean daily reflective Total Nasal Symptom Score (rTNSS) over the first 14 days and safety/secondary endpoints defined; enrollment will be timed to local allergy seasons.
Positives
- Completed contracting with all five planned U.S. clinical sites and advanced to study execution
- Trial is randomized single-blind, up to 120 patients (1:1 NASARIX vs saline), providing a defined efficacy/safety framework
- Primary endpoint (mean daily rTNSS over first 14 days) and multiple secondary/safety measures are specified
Negatives
- No clinical efficacy or safety data yet—first-in-human trial not completed
- First-in-human stage carries high clinical and developmental risk
- Enrollment is dependent on seasonal allergen timing, which could delay recruitment